RGNX REGENXBIO PE ratio, current and historical analysis
The current PE ratio of RGNX can't be determined, as the TTM EPS of -$4.59 is negative. The last PE ratio of REGENXBIO, recorded in September 2022, was 14.52.
RGNX PE ratio history
The PE ratio of REGENXBIO has averaged 17.2 over the last nine years. Over the past nine years, RGNX's PE ratio was at its highest in the Sep 2018 quarter at 29.49, when the stock price was $75.5 and the EPS was $2.56. The lowest value was in the Dec 2021 quarter, when it reached 10.86 with a price of $32.7 and an EPS of $3.01.
REGENXBIO PE ratio by year
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | N/A | N/A | $7.73 | -$4.59 |
| 2023 | N/A | N/A | $17.95 | -$6.02 |
| 2022 | N/A | N/A | $22.68 | -$6.5 |
| 2021 | 10.86 | N/A | $32.7 | $3.01 |
| 2020 | N/A | N/A | $45.36 | -$2.98 |
| 2019 | N/A | N/A | $40.97 | -$2.58 |
| 2018 | 14.03 | N/A | $41.95 | $2.99 |
| 2017 | N/A | N/A | $33.25 | -$2.45 |
| 2016 | N/A | N/A | $18.55 | -$2.38 |
| 2015 | N/A | N/A | $16.6 | -$2.59 |
| 2014 | N/A | N/A | N/A | -$1.82 |
| 2013 | N/A | N/A | N/A | -$2.5 |
REGENXBIO PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Dec 2024 | N/A | N/A | $7.73 | -$4.59 |
| Sep 2024 | N/A | N/A | $10.49 | -$5.02 |
| Jun 2024 | N/A | N/A | $11.7 | -$5.26 |
| Mar 2024 | N/A | N/A | $21.07 | -$5.87 |
| Dec 2023 | N/A | N/A | $17.95 | -$6.02 |
| Sep 2023 | N/A | N/A | $16.46 | -$5.99 |
| Jun 2023 | N/A | N/A | $19.99 | -$6.33 |
| Mar 2023 | N/A | N/A | $18.91 | -$6.25 |
| Dec 2022 | N/A | N/A | $22.68 | -$6.5 |
| Sep 2022 | 14.52 | 29.3% | $26.43 | $1.82 |
| Jun 2022 | 11.23 | -18.09% | $24.7 | $2.2 |
| Mar 2022 | 13.71 | 26.24% | $33.19 | $2.42 |
| Dec 2021 | 10.86 | N/A | $32.7 | $3.01 |
| Sep 2021 | N/A | N/A | $41.92 | -$5.16 |
| Jun 2021 | N/A | N/A | $38.85 | -$3.55 |
RGNX average PE ratio chart
RGNX PE vs peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| OLMA Olema Pharmaceuticals Inc | N/A | $230.28M |
| OMER Omeros Corp | N/A | $432M |
| ONVO Organovo Holdings Inc | N/A | $3.16M |
| ORIC Oric Pharmaceuticals Inc | N/A | $370.76M |
| ORMP Oramed Pharmaceuticals Inc | N/A | $89.46M |
| RGNX REGENXBIO Inc | N/A | $333.07M |
Frequently asked questions
What is REGENXBIO's PE ratio?
The current price to earnings ratio of RGNX can't be calculated, as its EPS of -$4.59 is negative.
What is the highest PE ratio for RGNX?
Over the last nine years, the quarterly PE ratio reached a historic high of 29.49 in the Sep 2018 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.